ACC.17

At the screening visit, there was no difference in HbA1c levels between the two treatment groups.

Patients with atrial fibrillation (AF) taking oral anticoagulants for stroke prevention face a higher risk of bleeding when taking concomitant antiplatelet agents.

Researchers analyzed 3 years of CV event rates using data from 7020 patients in the EMPA-REG OUTCOME study to understand the degree to which the emplagliflozin risk reduction may be explained.

Findings from the GEMINI-ACS-1 trial that evaluated the safety of low-dose rivaroxaban vs. aspirin daily in addition to a P2Y12 inhibitor (clopidogrel or ticagrelor) for ACS patients were presented.

Risk of mortality in HF patients with reduced kidney function taking ACE inhibitors and ARBs were evaluated.

Ten percent of patients developed intolerance to 2 medications while 1% had intolerance to 3 medications.

Older patients, males, patients with CHD, hypertension, diabetes, and those taking nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and protease inhibitors were more likely to be on a statin.

Incident intraventricular conduction delay(IVCD)—but not bundle branch block (BBB)—was significantly reduced by losartan-based treatment.